Cargando…

Immunotherapy for sarcomas: new frontiers and unveiled opportunities

Sarcomas are a rare malignancy of mesenchymal tissues, comprizing a plethora of unique subtypes, with more than 60 types. The sheer heterogeneity of disease phenotype makes this a particularly difficult cancer to treat. Radiotherapy, chemotherapy and surgery have been employed for over three decades...

Descripción completa

Detalles Bibliográficos
Autores principales: Birdi, Harsimrat Kaur, Jirovec, Anna, Cortés-Kaplan, Serena, Werier, Joel, Nessim, Carolyn, Diallo, Jean-Simon, Ardolino, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852926/
https://www.ncbi.nlm.nih.gov/pubmed/33526607
http://dx.doi.org/10.1136/jitc-2020-001580
_version_ 1783645888079462400
author Birdi, Harsimrat Kaur
Jirovec, Anna
Cortés-Kaplan, Serena
Werier, Joel
Nessim, Carolyn
Diallo, Jean-Simon
Ardolino, Michele
author_facet Birdi, Harsimrat Kaur
Jirovec, Anna
Cortés-Kaplan, Serena
Werier, Joel
Nessim, Carolyn
Diallo, Jean-Simon
Ardolino, Michele
author_sort Birdi, Harsimrat Kaur
collection PubMed
description Sarcomas are a rare malignancy of mesenchymal tissues, comprizing a plethora of unique subtypes, with more than 60 types. The sheer heterogeneity of disease phenotype makes this a particularly difficult cancer to treat. Radiotherapy, chemotherapy and surgery have been employed for over three decades and, although effective in early disease (stages I–II), in later stages, where metastatic tumors are present, these treatments are less effective. Given the spectacular results obtained by cancer immunotherapy in a variety of solid cancers and leukemias, there is now a great interest in appliying this new realm of therapy for sarcomas. The widespread use of immunotherapy for sarcoma relies on immuno-profiling of subtypes, immunomonitoring for prognosis, preclinical studies and insight into the safety profile of these novel therapies. Herein, we discuss preclinical and clinical data highlighting how immunotherapy is being used in soft tissue sarcoma and bone sarcomas.
format Online
Article
Text
id pubmed-7852926
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-78529262021-02-02 Immunotherapy for sarcomas: new frontiers and unveiled opportunities Birdi, Harsimrat Kaur Jirovec, Anna Cortés-Kaplan, Serena Werier, Joel Nessim, Carolyn Diallo, Jean-Simon Ardolino, Michele J Immunother Cancer Review Sarcomas are a rare malignancy of mesenchymal tissues, comprizing a plethora of unique subtypes, with more than 60 types. The sheer heterogeneity of disease phenotype makes this a particularly difficult cancer to treat. Radiotherapy, chemotherapy and surgery have been employed for over three decades and, although effective in early disease (stages I–II), in later stages, where metastatic tumors are present, these treatments are less effective. Given the spectacular results obtained by cancer immunotherapy in a variety of solid cancers and leukemias, there is now a great interest in appliying this new realm of therapy for sarcomas. The widespread use of immunotherapy for sarcoma relies on immuno-profiling of subtypes, immunomonitoring for prognosis, preclinical studies and insight into the safety profile of these novel therapies. Herein, we discuss preclinical and clinical data highlighting how immunotherapy is being used in soft tissue sarcoma and bone sarcomas. BMJ Publishing Group 2021-02-01 /pmc/articles/PMC7852926/ /pubmed/33526607 http://dx.doi.org/10.1136/jitc-2020-001580 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Birdi, Harsimrat Kaur
Jirovec, Anna
Cortés-Kaplan, Serena
Werier, Joel
Nessim, Carolyn
Diallo, Jean-Simon
Ardolino, Michele
Immunotherapy for sarcomas: new frontiers and unveiled opportunities
title Immunotherapy for sarcomas: new frontiers and unveiled opportunities
title_full Immunotherapy for sarcomas: new frontiers and unveiled opportunities
title_fullStr Immunotherapy for sarcomas: new frontiers and unveiled opportunities
title_full_unstemmed Immunotherapy for sarcomas: new frontiers and unveiled opportunities
title_short Immunotherapy for sarcomas: new frontiers and unveiled opportunities
title_sort immunotherapy for sarcomas: new frontiers and unveiled opportunities
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852926/
https://www.ncbi.nlm.nih.gov/pubmed/33526607
http://dx.doi.org/10.1136/jitc-2020-001580
work_keys_str_mv AT birdiharsimratkaur immunotherapyforsarcomasnewfrontiersandunveiledopportunities
AT jirovecanna immunotherapyforsarcomasnewfrontiersandunveiledopportunities
AT corteskaplanserena immunotherapyforsarcomasnewfrontiersandunveiledopportunities
AT werierjoel immunotherapyforsarcomasnewfrontiersandunveiledopportunities
AT nessimcarolyn immunotherapyforsarcomasnewfrontiersandunveiledopportunities
AT diallojeansimon immunotherapyforsarcomasnewfrontiersandunveiledopportunities
AT ardolinomichele immunotherapyforsarcomasnewfrontiersandunveiledopportunities